Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,757 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,046)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06962449 | Real-World Assessment of Therapeutic Strategies and Survival Outcomes Following First-Line Tislelizumab Therapy in Advanced Non-Small Cell Lung Cancer(REALM-Post) | enrolling by invitation | — | 500 | Shanghai Chest HospitalOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT06498986 | A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer | recruiting | Phase 2 | 40 | Sichuan Baili Pharmaceutical Co., Ltd. |
| 1 |
| May 7, 2025 |
| clinicaltrials |
| NCT02983578 | Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer | active not recruiting | Phase 2 | 39 | M.D. Anderson Cancer CenterOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT06401824 | Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases | recruiting | Phase 2 | 25 | Maastricht University Medical CenterOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT06955325 | Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations(UPLIFT) | not yet recruiting | Phase 3 | 270 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 0 | May 6, 2025 | clinicaltrials |
| NCT05621837 | Quantifying Systemic Immunosuppression to Personalize Cancer Therapy(Serpentine) | recruiting | — | 1,000 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT05352035 | Multiomics Tumor Evolution Model of NSCLC | recruiting | — | 300 | Peking University People's HospitalOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT05835570 | Integrin αvβ6-targeted PET in Malignant Tumors | recruiting | — | 200 | Zhongnan HospitalOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT05994131 | IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC | recruiting | Phase 1 / Phase 2 | 110 | InxMed (Shanghai) Co., Ltd.INDUSTRY | 1 | Apr 30, 2025 | clinicaltrials |
| NCT06718972 | A Real-world Study on the Treatment of Non-small Cell Lung Cancer With Leptomeningeal Metastasis in China(CLM-tree datab) | recruiting | — | 1,000 | Guangzhou Medical UniversityOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT06946836 | Comparison of Neoadjuvant Cadonilimab Versus Chemotherapy Combined With PD-1 in the Treatment of Resectable Non-Small Cell Lung Cancer With High PD-L1 Expression: A Single-Center, Randomized, Exploratory Clinical Study(Neoadjuvant) | not yet recruiting | Phase 2 | 80 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Apr 27, 2025 | clinicaltrials |
| NCT05736731 | A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression(EVEREST-1) | active not recruiting | Phase 1 / Phase 2 | 160 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT06942845 | Exploration of Risk Factors for Postoperative Cerebral Infarction in Lung Cancer Patients: a Retrospective Single-centre Study | active not recruiting | — | 300 | Xinghua ChengOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT06046495 | A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer | recruiting | Phase 1 | 81 | Avistone Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 23, 2025 | clinicaltrials |
| NCT06934590 | Evaluate Safety and Tolerability of RX001 in Patients With KRAS Mutant Advanced NSCLC | not yet recruiting | Phase 1 | 18 | GeneCraft Inc.INDUSTRY | 1 | Apr 23, 2025 | clinicaltrials |
| NCT06939127 | Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC | recruiting | Phase 2 | 38 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT05919537 | Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation | active not recruiting | Phase 1 | 68 | Hummingbird BioscienceINDUSTRY | 1 | Apr 18, 2025 | clinicaltrials |
| NCT06557187 | Hippocampus-Avoidance Whole-Brain Radiation Therapy With Simultaneous Integrated Boost for BMs of NSCLC | active not recruiting | N/A | 40 | Yatian LiuOTHER | 1 | Apr 18, 2025 | clinicaltrials |
| NCT06754930 | A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC | recruiting | Phase 1 / Phase 2 | 400 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 17, 2025 | clinicaltrials |
| NCT06930807 | Liquid Biopsy-Based Novel Modality for Postoperative Management of Lung Cancer | recruiting | N/A | 1,000 | Peking University People's HospitalOTHER | 1 | Apr 16, 2025 | clinicaltrials |
| NCT06925048 | SHR0302 Combined With PD-1/PD-L1 Inhibition for Treatment naïve or Acquired Resistant to Immunology NSCLC | not yet recruiting | Phase 2 | 86 | Chunxia SuOTHER | 0 | Apr 13, 2025 | clinicaltrials |
| NCT06926413 | A Study Evaluating the Effect of Aumolertinib on the Pharmacokinetics of Midazolam in Patients With NSCLC | recruiting | Phase 1 | 20 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 13, 2025 | clinicaltrials |
| NCT04654364 | Lung Cancer Registry | recruiting | — | 500 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT05275374 | XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation(ENHANCE) | not yet recruiting | Phase 1 / Phase 2 | 221 | Xynomic Pharmaceuticals, Inc.INDUSTRY | 0 | Apr 10, 2025 | clinicaltrials |
| NCT06922266 | Personalizing Adoptive Cell Transfer for Solid Tumors: Towards a New Patient-tailored Treatment Option(Chewbacca) | not yet recruiting | — | 20 | Ospedale San RaffaeleOTHER | 0 | Apr 10, 2025 | clinicaltrials |
| NCT06621563 | Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors(HS-20117) | recruiting | Phase 1 | 780 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Apr 9, 2025 | clinicaltrials |
| NCT06829459 | A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs | recruiting | Phase 3 | 350 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | Apr 8, 2025 | clinicaltrials |
| NCT06900283 | Quality of Life as a Predictor of OS and PFS in Patients With Lung Cancer(FACT-L_Pred) | active not recruiting | — | 320 | Instituto Nacional de Cancerologia, ColumbiaOTHER_GOV | 1 | Apr 3, 2025 | clinicaltrials |
| NCT06908733 | Integrating Surgery and Radiotherapy Following Tislelizumab-based Conversion Therapy in N3-Stage III NSCLC | not yet recruiting | Phase 2 | 30 | Liaoning Cancer Hospital & InstituteOTHER | 0 | Apr 3, 2025 | clinicaltrials |
| NCT05255302 | De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction(DIAL) | recruiting | Phase 2 / Phase 3 | 1,360 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT06107608 | Molecular Imaging of FAP Expressing Cancer-associated Fibroblasts in NSCLC Treated With Immune-checkpoint Inhibitors(LIFE) | recruiting | N/A | 58 | Jules Bordet InstituteOTHER | 1 | Mar 31, 2025 | clinicaltrials |
| NCT06775002 | SERS-Based Serum Molecular Spectral Screening for Lung Cancer Type | not yet recruiting | — | 223 | Fuzhou General HospitalOTHER | 0 | Mar 31, 2025 | clinicaltrials |
| NCT06690216 | Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors(PD-L1-PET) | enrolling by invitation | Phase 1 / Phase 2 | 100 | Man HuOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT04852588 | Chest Lymph Node Sampling in Patients With Advanced Lung Cancer to be Treated With Curative-intent Radiation Treatment | recruiting | N/A | 29 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT05473156 | A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies(APT-CUBE) | recruiting | Phase 1 / Phase 2 | 168 | AP Biosciences Inc.INDUSTRY | 1 | Mar 26, 2025 | clinicaltrials |
| NCT06889467 | Liquid Biopsy Assay of EBUS-TBNA Supernatant Fluid for Diagnosing Lung Cancer | recruiting | — | 10 | Barzilai Medical CenterOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT06896890 | Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 32 | Inhatarget TherapeuticsINDUSTRY | 3 | Mar 26, 2025 | clinicaltrials |
| NCT03978377 | Cardiopulmonary Toxicity of Thoracic Radiotherapy(CLARIFY) | recruiting | — | 320 | University Medical Center GroningenOTHER | 3 | Mar 25, 2025 | clinicaltrials |
| NCT06893354 | Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics | not yet recruiting | Phase 4 | 20 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 0 | Mar 25, 2025 | clinicaltrials |
| NCT04802876 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors(ACROPOLI) | active not recruiting | Phase 2 | 184 | SOLTI Breast Cancer Research GroupOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT06890182 | Firmonertinib Combined With Chemotherapy as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutanted NSCLC | not yet recruiting | Phase 2 | 31 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Mar 21, 2025 | clinicaltrials |
| NCT06885840 | Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification. | not yet recruiting | Phase 2 | 100 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Mar 20, 2025 | clinicaltrials |
| NCT05636969 | Multimodal Prehabilitation in Patients with Lung Cancer Undergoing Neoadjuvant Therapy | recruiting | N/A | 60 | Hospital Clinic of BarcelonaOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT06883136 | Efficacy and Safety of Sintilimab Combined with Platinum-containing Double-agent Chemotherapy in First-line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer in Elderly Patients | enrolling by invitation | — | 43 | Qianfoshan HospitalOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT04585035 | Study to Evaluate D-1553 in Subjects With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 180 | InventisBio Co., LtdINDUSTRY | 4 | Mar 18, 2025 | clinicaltrials |
| NCT06876675 | LORLATINIB-related HYPERLIPIDEMIA in ALK+ Non-Small Cell Lung Cancer | enrolling by invitation | — | 167 | Peking University Third HospitalOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT06617416 | A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC | recruiting | Phase 3 | 560 | AkesoINDUSTRY | 1 | Mar 12, 2025 | clinicaltrials |
| NCT06863506 | Phase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLC | recruiting | Phase 2 | 78 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06863818 | Overcoming Resistance to EGFR Neutralization by Combination of Monoclonal Antibodies and Novel Cancer Drugs | active not recruiting | — | 30 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Mar 7, 2025 | clinicaltrials |
Data updated 23 days agoSource updated May 8, 2025source: clinicaltrials